GlobeNewsWire
14 Oct 2026, 06:00 UTC · 4h ago
Impact · against what's priced in
Pharming's positive Phase II data for leniolisib in broader PIDs expands its addressable market beyond APDS and reduces the risk profile for future trials. This represents a material expansion of the drug's potential utility and peak sales expectations.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Pharming presented positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation today, October 14, 2026.
Newpresented today, October 14, 2026
So whatExpanding the target indication beyond APDS increases the addressable patient population and potential peak sales estimates.
More positive than 94% of claims this week
Continue reading
5 related stories
The data expands the potential patient population beyond APDS to other genetic PIDs with immune dysregulation and suggests strong tolerability via a 100% long-term extension enrollment rate.
Read from the article alone
Scored by the NIS engine · methodology.
Leniolisib demonstrated improvement in lymphoproliferation and positive trends in lung and liver disease markers.
Newpresented today, October 14, 2026
More positive than 80% of claims this week
All participants who completed the Phase II study elected to continue treatment in a long-term extension study.
Newpresented today, October 14, 2026
So whatA 100% extension rate reduces the perceived risk of late-stage attrition due to intolerable side effects.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company presented positive topline data from a Phase II trial for its drug leniolisib.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
8h ago
—
No price for PHARM right now — the quote feed didn't answer.
PHARM chart →
